{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["3(6)"],"submitter":["Seki Y"],"funding":["AMED","Japan Society for the Promotion of Science"],"pubmed_abstract":["<h4>Background</h4>The Omicron variant of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) was identified in Japan in November 2021. This variant contains up to 36 mutations in the spike protein, the target of neutralizing antibodies, and can escape vaccine-induced immunity. A booster vaccination campaign began with healthcare workers and high-risk groups. The safety and immunogenicity of the three-dose vaccination against Omicron remain unknown.<h4>Methods</h4>A total of 272 healthcare workers were initially evaluated for long-term vaccine safety and immunogenicity. We further established a vaccinee panel to evaluate the safety and immunogenicity against variants of concern (VOCs), including the Omicron variants, using a live virus microneutralization assay.<h4>Findings</h4>Tw"],"journal":["Med (New York, N.Y.)"],"pagination":["406-421.e4"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9040508"],"repository":["biostudies-literature"],"pubmed_title":["Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants."],"pmcid":["PMC9040508"],"pubmed_authors":["Sasaki K","Suzuki T","Fukushi S","Seki Y","Mizukami T","Takahashi Y","Yato Y","Moriyama S","Nojima K","Numata N","Kuzuoka T","Hamaguchi I","Yoshihara Y","Wagatsuma A","Maeda K","Momose H"],"additional_accession":[]},"is_claimable":false,"name":"Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.","description":"<h4>Background</h4>The Omicron variant of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) was identified in Japan in November 2021. This variant contains up to 36 mutations in the spike protein, the target of neutralizing antibodies, and can escape vaccine-induced immunity. A booster vaccination campaign began with healthcare workers and high-risk groups. The safety and immunogenicity of the three-dose vaccination against Omicron remain unknown.<h4>Methods</h4>A total of 272 healthcare workers were initially evaluated for long-term vaccine safety and immunogenicity. We further established a vaccinee panel to evaluate the safety and immunogenicity against variants of concern (VOCs), including the Omicron variants, using a live virus microneutralization assay.<h4>Findings</h4>Tw","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2026-05-09T15:10:55.749Z","creation":"2025-02-18T23:35:50.243Z"},"accession":"S-EPMC9040508","cross_references":{"pubmed":["35815933"],"doi":["10.1016/j.medj.2022.04.013"]}}